Peptide research spans more than a century, from the first synthesis of a dipeptide in 1901 to modern automated synthesis platforms producing thousands of analogs for drug discovery. This history traces the key innovations that made contemporary peptide science possible.
Early Discoveries (1900s–1950s)
Emil Fischer performed the first chemical synthesis of a peptide — glycylglycine — in 1901, establishing that amino acids could be linked by condensation reactions. In the following decades, researchers identified peptide hormones as critical biological mediators. Insulin was isolated in 1921 by Banting and Best, oxytocin’s structure was determined by Vincent du Vigneaud in 1953 (earning him the Nobel Prize), and ACTH was sequenced and synthesized shortly thereafter. These achievements demonstrated that peptides could be characterized, synthesized, and studied as discrete chemical entities.
Frederick Sanger’s development of protein sequencing methods in the 1950s, using insulin as his model system, provided the tools needed to determine peptide primary structures. His work established that each protein has a unique, defined amino acid sequence — a foundational concept for all subsequent peptide chemistry.
The SPPS Revolution (1960s–1990s)
Robert Bruce Merrifield’s invention of solid-phase peptide synthesis in 1963 transformed the field. By anchoring the growing peptide chain to an insoluble resin support, Merrifield eliminated the need for laborious purification after each amino acid coupling step. This innovation reduced synthesis time from months to days and earned Merrifield the 1984 Nobel Prize in Chemistry. The Fmoc protection strategy, developed by Louis Carpino in 1972 and refined through the 1980s, offered a milder alternative to Merrifield’s original Boc chemistry and became the standard for most laboratories.
Automation followed rapidly. By the 1990s, commercial peptide synthesizers could perform unattended synthesis of peptides up to 50 residues long. Combinatorial chemistry approaches — including split-and-mix libraries and parallel synthesis — enabled screening of thousands of peptide sequences for biological activity, accelerating drug discovery efforts.
Modern Peptide Science (2000s–Present)
The 21st century has seen peptides transition from research tools to a major pharmaceutical class. Advances in stapled peptides, bicycle peptides, and peptide-drug conjugates have expanded the scope of peptide-based therapeutics. Computational approaches now predict peptide structures and binding affinities, guiding rational design. High-throughput synthesis platforms produce hundreds of analogs simultaneously, while improved analytical methods characterize peptides at unprecedented resolution. Peptides represent one of the fastest-growing segments of the pharmaceutical and research reagent markets.
Frequently Asked Questions
Who is considered the father of peptide synthesis?
Bruce Merrifield is widely regarded as the father of modern peptide synthesis for his invention of SPPS. Emil Fischer pioneered the earliest peptide synthesis work, while Vincent du Vigneaud achieved the first synthesis of a biologically active peptide hormone (oxytocin) in 1953.
When did peptides become commercially available for research?
Custom peptide synthesis services became commercially available in the 1980s as SPPS automation matured. Catalog research peptides — pre-synthesized sequences available for immediate purchase — became widespread in the 1990s. Today, hundreds of suppliers offer both custom and catalog peptides worldwide.